人工会成柞蚕杀菌肽D基因的克隆及在大肠杆菌中的表达

以质粒pWR450为载体,克隆了人工合成的柞蚕杀菌肽D基因(122bp),构建的重组子pWR450-Cec转化大肠杆菌JM103、用限制性内切酶酶切鉴定。产物经SDS-聚丙烯酰胺凝胶电泳,结果显示可表达杀菌肽-β-gal融合蛋白。     

Gene therapy for hemophilia B mediated by recombinant adeno-associated viral vector with hFIXR338A, a high catalytic activity mutation of human coagulation factor IX

A mutant human factor IX with arginine at 338 residual changed to alanine (hFIXR338A) by site-directed mutagenesis was introduced into AAV vectors, and a recombinant adeno-associ-ated viral vector containing hFIXR338A, prepared by rHSV/AAV hybrid helper virus system, was directly introduced to the hind leg muscle of factor IX knock out mice. The expression and the biological activity of human factor IX mutant, hFIXR338A, and the immune response against it in the treated mice were assayed and detected. The results showed that (i) the high-level expression of human factor IX mutant protein, hFIXR338A, has been detected in rAAV-hFIXR338A treated hemophilia B mice and lasted more than 15 weeks; (ii) the clotting activity of hFIXR338A in plasma is 34.2%± 5.23%, which is remarkably higher than that of (14.27%±3.4%) of wild type hFIX treated mice in the activated partial thromboplastin assay; (iii) immune response against factor IX R338A was absent, with no factor IX mutant protein (hFIXR338A) inhibitors deve     

A novel and highly efficient production system for recombinant adeno-associated virus vector

Recombinant adeno-associated virus (rAAV) has proven to be a promising gene delivery vector for human gene therapy. However, its application has been limited by difficulty in obtaining enough quantities of high-titer vector stocks. In this paper, a novel and highly efficient production system for rAAV is described. A recombinant herpes simplex virus type 1 (rHSV-1) designated HSV1-rc/AUL2, which expressed adeno-associated virus type2 (AAV-2) Rep and Cap proteins, was constructed previously. The data confirmed that its functions were to support rAAV replication and packaging, and the generated rAAV was infectious. Meanwhile, an rAAV proviral cell line designated BHK/SG2, which carried the green fluorescent protein (GFP) gene expression cassette, was established by transfecting BHK-21 cells with rAAV vector plasmid pSNAV-2-GFP. Infecting BHK/SG2 with HSV1-rc/AUL2 at an MOI of 0.1 resulted in the optimal yields of rAAV, reaching 250 transducing unit (TU) or 4.28×104 particles per cell. Therefore, compared     

以粘粒为基础产生重组单纯疱疹病毒HSV1—lacZ的研究

将总长主为１５２ｋｂ的单纯疱疹病毒１型基因组分成５个相互间有部分重叠的大片段,分别克隆到粘粒ＳｕｐｅｒＣｏｓＭＷ中,依次称为ｃｏｓ４８、ｃｏｓ２８、ｃｏｓ６、ｃｏｓ１４和ｃｏｓ５６（ＤａｖｉｓｏｎＡＪｅｔａｌ,１９９３）。此５个粘粒用ＰａｃＩ切去粘粒骨架后共转染细胞,可发生同源重组而产生野生型ＨＳＶ－１。     

肌注腺伴随病毒基因治疗血友病B的安全性研究

研究了肌注腺伴随病毒（adeno-associated virus,AAV）介导凝血Ⅸ因子基因治疗血友病B的安全性,道德采用PCR、反转录PCR（RT－PCR）分别检测rHSV/AAV包装系统产生的重组腺伴随病毒AAV－mFⅨ,和病毒感染细胞后所得上清再次感染的BHK细胞中的HSV（herpes simplex virus,HSV)和野生型AAV。同时观察HSV引起的细胞毒作用。结果表明：纯化后的AA－mFⅨ中HSV≤1个病毒基因组（viral genome,v.g.)/10^8个病毒基因组AAV－mFⅨ,且不具备感染活性;没有野生型AAV。其次,采用PCR、RT－PCR1免疫组化等方法检测了AAV－mFⅨ在体内的分布和表达时间;通过抗AAV的抗体检测和病理切片等方法观察了AAV－mFⅨ在体内引起的免疫反应和病理变化。结果表明：AAV－mFⅨ仅分布在注射点肌肉组织内,表达可持续200天以上;抗体水平低,各主要脏器均未发生明显的病理变化。AAV介导的凝血因子Ⅸ系统是安全的。     

重组腺相关病毒(rAAV)介导的人凝血因子Ⅸ高活性突变衍生物在血友病B基因治疗研究中的应用

采用定点诱变技术, 将R338A点突变引入人凝血因子Ⅸ基因, 并构建于AAV载体上, 以rHSV/AAV杂合辅助病毒系统介导制备rAAV-hFIX重组病毒, 然后, 经肌肉注射对血友病B小鼠进行治疗实验, 观察该突变基因在小鼠体内的表达、活性以及机体对该突变衍生物的免疫反应与治疗效果. 结果显示: (i)治疗小鼠体内可检测到hFIX-R338A突变衍生物的存在, 并持续15周以上; (ii)突变衍生物hFIX-R338A在小鼠血浆中的凝血活性达(34.2±5.23)%, 显著高于野生型Ⅸ因子凝血活性((14.27±3.4)%); (iii)治疗小鼠体内未检测到抗Ⅸ因子突变衍生物抗体的存在; (iv)未发现与治疗相关的局部及全身性毒副作用. 提示: 以AAV介导人凝血因子Ⅸ高活性突变衍生物hFIX-R338A基因治疗可能成为替代野生型Ⅸ因子进行血友病B基因治疗的一个更为有效的途径.     

A novel recombinant adeno-associated virus vector packaging system with HSV-1 amplicon providing helper functions

A novel packaging system for producing recombinant adeno-associated virus (rAAV) vector was described. Instead of the conventional method for rAAV production by two-plasmid co-transfection followed by superinfection with adenovirus 5, an HSV-1 amplicon system expressing AAV-2 rep and cap genes from their native promoters was used to provide complete helper functions for rAAV replicating and packaging. This HSV-1 ampticon stock consisted of two kinds of infectious HSV-1 virions, a replicating-defective HSV-1 amplicon pseudovirus harboring multi-copies of AAV-2 rep and cap gene and a temperature-sensitive HSV-1 mutant strain ts-KOS. High-titer rAAV was generated with this new packaging system. This packaging system gives a simple and scaleable process for rAAV production.     

重组腺相关病毒2型转导人外周血单核细胞来源树突状细胞的研究

To find out the infection efficiency of recombinant adeno-as sociated virus 2-mediated exogenou s genes in human peripheral blood monocyte-derived dendritic cells(D Cs),the process of transfection wa s investigated by FITC-labeled rAA V2,and observed under confocal mic roscope.Newly separated dendritic cells were tranfected by rAAV2-luc and rAAV2-GFP at different MOI,and transfection efficiency were detec ted by luminometer for rAAV2-luc a nd flow cytometry for rAAV2-GFP.Th e results were elucidated in four different assay systems:(1)60min w as needed for rAAV2 to bind on den dritic cells,and got into cells in the following 10min;(2)the express ion of luc could be detected at th e MOI as low as 1×10~5v.g/cell,and the expression plateau was reached by the MOI of 10~6～10~7v.g/cell,furt her increase of MOI had no functio n on expression level;(3)transgene expression was detected after 48h, and maintained a higher expression level from 96h to 240h after infec tion;(4)7days postinfection of rAA V2-GFP,5%～18% dendritic cells were GFP positive. These data suggest th at rAAV2 vector can efficiently in fect monocyte-derived dendritic ce lls and mediate exogenous gene exp ression,and that the application o f rAAV2 as vector may be useful fo r gene transfer to dendritic cells in ex vivo immunotherapy.     

用“乒乓效应”提高包装细胞培养上清中逆转录病毒滴度的方法

逆转录病毒是基因治疗研究中最为主要的基因转移载体,目前批准的基因治疗试验方案中绝大多数采用逆转录病毒作为载体。逆转录病毒具有稳定、安全、高效的优点,但仍存在病毒滴度低的问题。目前多从质粒结构和病毒包装两方面来提高病毒滴度。 将HyTK基因替换逆转录病毒载体GlNa